Pharmaceuticals

A new bispecific antibody aims to treat the 50% of AxSpA patients who find no relief, as Fortitude Biomedicines enters a competitive autoimmune market.

A US-Uruguay collaboration is using novel REJOIN-seq tech to find hidden RNA triggers of lupus, paving the way for safer, non-immunosuppressive drugs.

Ontario and Quebec expand public coverage for a potent cholesterol drug, offering a critical lifeline to thousands at risk of a second cardiovascular event.

A new report reveals a major education gap in obesity care. Informed patients are now demanding options beyond blockbuster drugs like Wegovy and Zepbound.

As employers face staggering GLP-1 expenses, a new program aims to deliver measurable outcomes by integrating clinical support directly into pharmacy benefits.

A new poll shows two-thirds of workers are more likely to use GLP-1s with employer coverage, highlighting the role of cost, support, and stigma.

Life Sciences Ontario's new board appointments signal a strategic shift, bringing in leaders from medtech, agri-tech, pharma, and nuclear isotopes.

As AI struggles to separate medical fact from fiction, a new .med domain offers a structural signal of trust, aiming to protect patients and verify sources.

AIRNA has dosed the first patient with AIR-001, an RNA-editing drug that could treat both the lung and liver damage of a devastating genetic disease.

A new Montreal-based collaboration aims to use advanced AI and a unique dataset to make drug development faster, smarter, and safer for patients.

Avaí Bio and Austrianova are set to present new findings on a novel cell-based therapy designed to produce the 'longevity protein' Klotho.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

A new botanical drug candidate, NFL-102, targets the deep neural roots of addiction, moving beyond symptom management to offer a lasting cure for smokers.

With diagnostic sales fueling a diverse therapeutic arsenal, Telix reaffirms blockbuster guidance and advances pivotal trials for prostate, brain, and kidney cancers.

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

Boston's Bio-IT World conference shifts from AI theory to execution, showcasing how the life sciences industry is now deploying AI to accelerate new therapies.

With a multi-billion dollar track record of IPOs and acquisitions, the veteran CEO's appointment signals Frazier's focus on navigating complex markets.

At AAN 2026, SK Life Science will present new cenobamate data and survey findings that expose a critical communication gap in epilepsy care.

A long-acting ketamine injection shows promise in treating severe depression without the harsh side effects and monitoring, potentially expanding access for millions.

New preclinical data for ATNM-400 and Actimab-A shows promise for treating resistant solid tumors and AML, highlighting a new frontier in cancer therapy.